Cerritos, California-based Revolve, an online fashion retailer, has filed for an IPO. The number of shares that will be sold as well as its pricing terms have yet to be set. Revolve plans on listing the stock on the New York Stock Exchange under the ticker symbol "RVLV." Morgan Stanley, Credit Suisse Securities (USA) LLC and BofA Merrill Lynch will serve as lead underwriters. Revolve is backed by TSG Consumer Partners.
Canadian private equity firm Onex Corp has taken SIG Combibloc Group AG public on the SIX Swiss Exchange. SIG, a Swiss provider of aseptic carton packaging solutions for the food and beverage industry, priced its shares at 11.25 Swiss francs per unit. Reuters reported the company is expected to raise 1.49 billion francs (US$1.53 billion) before the initial public offering (IPO)'s greenshoe option. Onex, which acquired SIG in 2015, is selling shares as part of the IPO. Its proceeds will be about US$300 million, excluding the greenshoe. Onex will continue to hold a 57 percent interest.
SIG Combibloc priced its initial public offering at 11.25 Swiss francs per share in a deal that raises 1.49 billion francs (US$1.53 billion) before an overallotment option and values the Swiss packaging maker at around 3.6 billion francs, it said before its market debut on Friday. As well as new shares being issued to reduce debt, Canadian private equity firm Onex Corp, majority owner of the drinks packaging company since 2015, and SIG management are also selling some of their existing holdings. The offer price, which Reuters had reported on Thursday, was towards the lower end of the 11 to 12 franc price range the company had flagged this week.
Gateway Casinos & Entertainment Ltd, a Vancouver-based gaming and entertainment company, has filed a draft registration with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO) of its common shares. The IPO, which has not yet been priced, is expected to commence following the SEC's review and subject to market and other conditions. Founded in 1992, Gateway operates 25 gaming properties with more than 280 tables, over 9,600 slots, 68 restaurants and bars and 272 hotel rooms. It recently expanded operations in Ontario. Gateway was acquired in 2010 by Canadian private equity firm Catalyst Capital Group, which restructured the business.
Palo Alto, California-based Kodiak Sciences Inc, a biopharmaceutical company focused on treating chronic retinal diseases, has priced its IPO of 9 million shares at between $13 and $15 per share. Kodiak will list the stock on the NASDAQ under the ticker symbol "KOD." Morgan Stanley and BofA Merrill Lynch are the lead underwriters. Kodiak is backed by ArrowMark Partners and Perceptive Advisors, according to Crunchbase.
New York and Denver-based Y-mAbs Therapeutics, a developer of cancer treatments, has raised $96 million for its IPO after pricing its 6 million shares at $16 per share. The stock began trading September 21, 2018 on the NASDAQ under the ticker symbol "YMAB." BofA Merrill Lynch and Cowen are the lead underwriers. Y-mAbs Therapeutics Inc' pre-IPO investors included Sofinnova Ventures and Scopia Capital Management.
In Second Opinion, Facebook rolls out its new dating feature in Colombia, multiple people are shot in a Maryland Rite Aid warehouse and Aston Martin is seeking to raise $6.7 billion for its IPO.
Eventbrite has priced its IPO at 10 million shares at $23 each, according to a Sept. 20 SEC filing. This is up from its original $19 to $21 price range that it increased to $21 to $23 on Tuesday, Sept. 18. Eventbrite, which provides an online ticketing platform, expects to trade on the NYSE under the ticker “EB.” After the IPO, Tiger Global will own 20.9 percent of voting power, while Sequoia Capital will have 20 percent and T. Rowe Price will have 6.8 percent, the regulatory filing said.
South San Francisco-based Principia Biopharma, a biopharmaceutical company focused on "bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology," has raised about $106.25 million for its IPO after pricing its 6.25 million shares at $17 per share. The stock began trading September 14, 2018 on the NASDAQ under the ticker symbol "PRNB." BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities are the lead underwriters. Principia Biopharma's pre-IPO investors included Sofinnova Ventures, Morgenthaler Ventures, New Leaf Venture Partners, OrbiMed, SR One and Mission Bay Capital.
Chinese electric vehicle start-up NIO Inc (NIO.N) priced its shares near the bottom of its targeted price range in its U.S. initial public offering, according to sources familiar with the matter, dragged down by investor concerns about the prospects of chief competitor Tesla Inc (TSLA.O).